Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.68 |
| ▸ | STS | P08842 | 5/20 | 0.65 |
| ▸ | ESR1 | P03372 | 9/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.64 |
| ▸ | AR | P10275 | 4/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.64 |
| ▸ | SNCA | P37840 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 3/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864592 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL712443 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL29643366 | 1.00 | SHBG (1.00) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL28373123 | 0.90 | SHBG (0.81) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL6695130 | 0.86 | SHBG (0.75) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL5143409 | 0.85 | SHBG (0.74) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL8606752 | 0.84 | SHBG (0.72) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL23027370 | 0.84 | SHBG (0.71) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL2232239 | 0.84 | STS (0.74) | SHBGHSD17B1STSESR1ESR2 | |
| SCHEMBL23645588 | 0.84 | STS (0.74) | SHBGHSD17B1STSESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2625190-B1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC, ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | UNIV JUSTUS LIEBIG GIESSEN (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2013-01-31 | — | — | US | disclosed |
| US-8236565-B2 | Tagging reagents and methods for hydroxylated compounds | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2012-08-07 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | Pradama, Inc. | 2012-04-05 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| WO-2009047343-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-16 | — | — | WO | disclosed |
| EP-1310508-B1 | Estrogen sulfamate sulphatase inhibitors | STERIX LTD (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080014642-A1 | TAGGING REAGENTS AND METHODS FOR HYDROXYLATED COMPOUNDS | APPLIED BIOSYSTEMS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | TRIN GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | GPER1, SHBG, GNRHR | SHBG 2/4885HSD17B1 81/4885STS 112/4885 |
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | SHBG 14/4885HSD17B1 663/4885STS 1447/4885 |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | SHBG 180/4885HSD17B1 2180/4885STS 852/4885 |
| US-20080112888-A1 | IGFBP2 BIOMARKER | IGFBP2, IGFBP1, IGFBP5 | SHBG 14/4885HSD17B1 663/4885STS 1447/4885 |
| US-20120083440-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | SHBG 64/4885HSD17B1 3580/4885STS 3742/4885 |
| US-20080014642-A1 | TAGGING REAGENTS AND METHODS FOR HYDROXYLATED COMPOUNDS | DHCR7, SRMS, CYP21A2 | SHBG 14/4885HSD17B1 31/4885STS 60/4885 |
| US-20110014117-A1 | ANTI-IGF1R | IGF1R, IGFBP1, IGFBP2 | SHBG 45/4885HSD17B1 3020/4885STS 3816/4885 |
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | SHBG 518/4885HSD17B1 2876/4885STS 3336/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | SHBG 2859/4885HSD17B1 3701/4885STS 4013/4885 |
| US-20130029901-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | SHBG 64/4885HSD17B1 3580/4885STS 3742/4885 |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, KLK3, CD44 | SHBG 23/4885HSD17B1 2575/4885STS 4550/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | SHBG 96/4885HSD17B1 2521/4885STS 2851/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | SHBG 323/4885HSD17B1 1467/4885STS 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.